The gap at .071/.072 closed. .071 is also strong support. Surprised at the selling as the news is pivotal but TA bounce expected here. Very undervalued.
The role of CBD is getting traction for COVID even in generic form, let alone the IHL proprietary advanced compound.
- Forums
- ASX - By Stock
- Ann: Positive Results from IHL-675 (ARDS) animal study
The gap at .071/.072 closed. .071 is also strong support....
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online